Loading…

Budesonide bests COVID-19

Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide tw...

Full description

Saved in:
Bibliographic Details
Published in:Canadian family physician 2022-05, Vol.68 (5), p.355-355
Main Authors: Moe, Samantha S, Allan, G Michael, Train, Anthony
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 355
container_issue 5
container_start_page 355
container_title Canadian family physician
container_volume 68
creator Moe, Samantha S
Allan, G Michael
Train, Anthony
description Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide twice a day for 14 days. Compared with usual care, budesonide shortened the time to recovery, increased the proportion of patients recovering by day 14, and reduced the need for health services. Outpatients with COVID-19 have a growing number of treatments available to them. Antiviral agents (nirmatrelvir-ritonavir) and monoclonal antibodies (eg, sotrovimab) appear to reduce the risk of death or hospitalization, but patient eligibility and access vary by jurisdiction. Family physicians can provide inhaled budesonide at the point of care to those not eligible for antiviral agents or monoclonal antibodies. Fluvoxamine is also available, but its benefits are less certain than those of other treatments.
doi_str_mv 10.46747/cfp.6805355
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9097727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2664797470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-dc42b847b39df6546a07529c52257fb8fdc63b335c84d5ba06fcdff40f03c1d93</originalsourceid><addsrcrecordid>eNpdkDtLA0EURgdRTIx2NjYSsLFw4533TiNofAUCaVTsht156IbNbrKTFfz3TkwMajXFHA73OwgdYxgwIZm8NH4-EClwyvkO6mKJecIJT3dRFwDShHJ47aCDEKYARDCK91EnopwQzLro5Ka1LtRVYV0_d2EZ-sPJy-g2weoQ7fmsDO5o8_bQ8_3d0_AxGU8eRsPrcWKoUMvEGkbylMmcKusFZyIDyYky0c-lz1NvjaA5pdykzPI8A-GN9Z6BB2qwVbSHrtbeeZvPnDWuWjZZqedNMcuaT11nhf77UxXv-q3-0AqUlERGwflG0NSLNm7QsyIYV5ZZ5eo2aCIEkyqWgoie_UOnddtUcd6K4likiq-oizVlmjqExvntMRj0d3Mdm-tN84if_h6whX8i0y99pHqb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2665168950</pqid></control><display><type>article</type><title>Budesonide bests COVID-19</title><source>PubMed Central</source><creator>Moe, Samantha S ; Allan, G Michael ; Train, Anthony</creator><creatorcontrib>Moe, Samantha S ; Allan, G Michael ; Train, Anthony</creatorcontrib><description>Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide twice a day for 14 days. Compared with usual care, budesonide shortened the time to recovery, increased the proportion of patients recovering by day 14, and reduced the need for health services. Outpatients with COVID-19 have a growing number of treatments available to them. Antiviral agents (nirmatrelvir-ritonavir) and monoclonal antibodies (eg, sotrovimab) appear to reduce the risk of death or hospitalization, but patient eligibility and access vary by jurisdiction. Family physicians can provide inhaled budesonide at the point of care to those not eligible for antiviral agents or monoclonal antibodies. Fluvoxamine is also available, but its benefits are less certain than those of other treatments.</description><identifier>ISSN: 0008-350X</identifier><identifier>EISSN: 1715-5258</identifier><identifier>DOI: 10.46747/cfp.6805355</identifier><identifier>PMID: 35552214</identifier><language>eng</language><publisher>Canada: College of Family Physicians of Canada</publisher><subject>Antiretroviral drugs ; Antiviral drugs ; Bronchodilator Agents ; Budesonide - therapeutic use ; Clinical outcomes ; Clinical trials ; COVID-19 ; Family physicians ; Hospitalization ; Humans ; Monoclonal antibodies ; SARS-CoV-2 ; Steroids ; Tools for Practice</subject><ispartof>Canadian family physician, 2022-05, Vol.68 (5), p.355-355</ispartof><rights>Copyright College of Family Physicians of Canada May 1, 2022</rights><rights>Copyright © 2022 the College of Family Physicians of Canada 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097727/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097727/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35552214$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moe, Samantha S</creatorcontrib><creatorcontrib>Allan, G Michael</creatorcontrib><creatorcontrib>Train, Anthony</creatorcontrib><title>Budesonide bests COVID-19</title><title>Canadian family physician</title><addtitle>Can Fam Physician</addtitle><description>Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide twice a day for 14 days. Compared with usual care, budesonide shortened the time to recovery, increased the proportion of patients recovering by day 14, and reduced the need for health services. Outpatients with COVID-19 have a growing number of treatments available to them. Antiviral agents (nirmatrelvir-ritonavir) and monoclonal antibodies (eg, sotrovimab) appear to reduce the risk of death or hospitalization, but patient eligibility and access vary by jurisdiction. Family physicians can provide inhaled budesonide at the point of care to those not eligible for antiviral agents or monoclonal antibodies. Fluvoxamine is also available, but its benefits are less certain than those of other treatments.</description><subject>Antiretroviral drugs</subject><subject>Antiviral drugs</subject><subject>Bronchodilator Agents</subject><subject>Budesonide - therapeutic use</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>COVID-19</subject><subject>Family physicians</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Monoclonal antibodies</subject><subject>SARS-CoV-2</subject><subject>Steroids</subject><subject>Tools for Practice</subject><issn>0008-350X</issn><issn>1715-5258</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdkDtLA0EURgdRTIx2NjYSsLFw4533TiNofAUCaVTsht156IbNbrKTFfz3TkwMajXFHA73OwgdYxgwIZm8NH4-EClwyvkO6mKJecIJT3dRFwDShHJ47aCDEKYARDCK91EnopwQzLro5Ka1LtRVYV0_d2EZ-sPJy-g2weoQ7fmsDO5o8_bQ8_3d0_AxGU8eRsPrcWKoUMvEGkbylMmcKusFZyIDyYky0c-lz1NvjaA5pdykzPI8A-GN9Z6BB2qwVbSHrtbeeZvPnDWuWjZZqedNMcuaT11nhf77UxXv-q3-0AqUlERGwflG0NSLNm7QsyIYV5ZZ5eo2aCIEkyqWgoie_UOnddtUcd6K4likiq-oizVlmjqExvntMRj0d3Mdm-tN84if_h6whX8i0y99pHqb</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Moe, Samantha S</creator><creator>Allan, G Michael</creator><creator>Train, Anthony</creator><general>College of Family Physicians of Canada</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202205</creationdate><title>Budesonide bests COVID-19</title><author>Moe, Samantha S ; Allan, G Michael ; Train, Anthony</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-dc42b847b39df6546a07529c52257fb8fdc63b335c84d5ba06fcdff40f03c1d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiretroviral drugs</topic><topic>Antiviral drugs</topic><topic>Bronchodilator Agents</topic><topic>Budesonide - therapeutic use</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>COVID-19</topic><topic>Family physicians</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Monoclonal antibodies</topic><topic>SARS-CoV-2</topic><topic>Steroids</topic><topic>Tools for Practice</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moe, Samantha S</creatorcontrib><creatorcontrib>Allan, G Michael</creatorcontrib><creatorcontrib>Train, Anthony</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian family physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moe, Samantha S</au><au>Allan, G Michael</au><au>Train, Anthony</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Budesonide bests COVID-19</atitle><jtitle>Canadian family physician</jtitle><addtitle>Can Fam Physician</addtitle><date>2022-05</date><risdate>2022</risdate><volume>68</volume><issue>5</issue><spage>355</spage><epage>355</epage><pages>355-355</pages><issn>0008-350X</issn><eissn>1715-5258</eissn><abstract>Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide twice a day for 14 days. Compared with usual care, budesonide shortened the time to recovery, increased the proportion of patients recovering by day 14, and reduced the need for health services. Outpatients with COVID-19 have a growing number of treatments available to them. Antiviral agents (nirmatrelvir-ritonavir) and monoclonal antibodies (eg, sotrovimab) appear to reduce the risk of death or hospitalization, but patient eligibility and access vary by jurisdiction. Family physicians can provide inhaled budesonide at the point of care to those not eligible for antiviral agents or monoclonal antibodies. Fluvoxamine is also available, but its benefits are less certain than those of other treatments.</abstract><cop>Canada</cop><pub>College of Family Physicians of Canada</pub><pmid>35552214</pmid><doi>10.46747/cfp.6805355</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-350X
ispartof Canadian family physician, 2022-05, Vol.68 (5), p.355-355
issn 0008-350X
1715-5258
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9097727
source PubMed Central
subjects Antiretroviral drugs
Antiviral drugs
Bronchodilator Agents
Budesonide - therapeutic use
Clinical outcomes
Clinical trials
COVID-19
Family physicians
Hospitalization
Humans
Monoclonal antibodies
SARS-CoV-2
Steroids
Tools for Practice
title Budesonide bests COVID-19
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T09%3A21%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Budesonide%20bests%20COVID-19&rft.jtitle=Canadian%20family%20physician&rft.au=Moe,%20Samantha%20S&rft.date=2022-05&rft.volume=68&rft.issue=5&rft.spage=355&rft.epage=355&rft.pages=355-355&rft.issn=0008-350X&rft.eissn=1715-5258&rft_id=info:doi/10.46747/cfp.6805355&rft_dat=%3Cproquest_pubme%3E2664797470%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-dc42b847b39df6546a07529c52257fb8fdc63b335c84d5ba06fcdff40f03c1d93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2665168950&rft_id=info:pmid/35552214&rfr_iscdi=true